Your browser doesn't support javascript.
loading
Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis.
Roumiguié, Mathieu; Paoletti, Xavier; Neuzillet, Yann; Mathieu, Romain; Vincendeau, Sebastien; Kleinclauss, François; Mejean, Arnaud; Guy, Laurent; Timsit, Marc Olivier; Lebret, Thierry.
Affiliation
  • Roumiguié M; Department of Urology, CHU-Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Paoletti X; Department of Public health, University of Versailles, Saint-Quentin, France.
  • Neuzillet Y; Institut Curie, INSERM U900, Biostatistics for Personalized Medicine, Saint-Cloud, France.
  • Mathieu R; Department of Urology, Hôpital Foch, University of Paris-Saclay, Versailles Saint-Quentin-en-Yvelines, Suresnes, France.
  • Vincendeau S; Department of Urology, Univ rennes, CHU Rennes, Inserm, EHESP, Irset - UMR_S 1085, F 35000 Rennes, France.
  • Kleinclauss F; Department of Urology, Centre Hospitalier Privé Saint Grégoire, Saint-Grégoire, France.
  • Mejean A; Department of Urology, Andrology & Kidney Transplantation, University of Franche-Comté, Besançon, France.
  • Guy L; Department of Urology, Hôpital Europeen Georges-Pompidou (HEGP), AP-HP, Paris, France.
  • Timsit MO; Department of Urology, CHU Clermont-Ferrand, UMR1240 INSERM, Université Clermont-Auvergne, Clermont Ferrand, France.
  • Lebret T; Department of Urology, Hôpital Europeen Georges-Pompidou (HEGP), AP-HP, INSERM, PARCC, Paris, France.
Future Oncol ; 17(14): 1811-1823, 2021 May.
Article in En | MEDLINE | ID: mdl-33543650
ABSTRACT

Aim:

Comparison of the efficacy/safety/health-related quality of life of apalutamide, enzalutamide and darolutamide in Phase III clinical trials involving patients with nonmetastatic castration-resistant prostate cancer was performed. Materials &

methods:

Relevant studies were identified by searching PubMed as well as conference abstracts reporting updated overall survival. Three pivotal trials were identified, SPARTAN (apalutamide), PROSPER (enzalutamide) and ARAMIS (darolutamide), and form the basis of this analysis.

Results:

All three drugs significantly prolonged metastasis-free survival, prostate-specific antigen response and overall survival versus placebo, and were generally well tolerated.

Conclusion:

Drug selection will likely be influenced by tolerability/safety and other factors, such as the propensity for drug-drug interactions and the presence of comorbidities, that affect the risk-benefit balance in individual patients.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylthiohydantoin / Pyrazoles / Thiohydantoins / Benzamides / Prostatic Neoplasms, Castration-Resistant / Nitriles Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies / Systematic_reviews Limits: Humans / Male Language: En Journal: Future Oncol Year: 2021 Type: Article Affiliation country: France
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylthiohydantoin / Pyrazoles / Thiohydantoins / Benzamides / Prostatic Neoplasms, Castration-Resistant / Nitriles Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies / Systematic_reviews Limits: Humans / Male Language: En Journal: Future Oncol Year: 2021 Type: Article Affiliation country: France